Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Asia-Pacific

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

RevMed and BeOne have partnered to advance clinical trials in Asia, while MoonLake has announced a successful Phase 3 clinical trial result.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your entry to Asian clinical trials just got easier through a new partnership, and a Phase 3 win signals a clearer path to market validation; push your regulatory and trial strategies in this region now.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialsasia-pacificbiotech-dealsphase-3-success